Skip to content

CancerIndexthe global index of cancer

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Cancers Data Trials Drugs Genes Biomarkers Approvals Rankings Research gap Graph

Pulse Data updates Year in cancer Taxonomy Countries Compare Trial intelligence Trial map Drug pipeline Sources Methodology About Trust & policies Data downloads Developers (API)

Loading cancer entity…

CancerIndex

CancerIndex is a research and information platform. It is not a physician, does not diagnose, and does not recommend treatment. Population statistics do not predict individual outcomes.

Every number links to its source and retrieval date. Derived metrics carry a formula version. AI-generated synthesis is not enabled in this phase; all content is database-grounded.

About Trust & policies Data explorer Data downloads Pulse Data update log Developers (API)Sources Methodology Taxonomy Countries Compare Contact · contact@spboucher.ai Status

© 2026 CancerIndex · built and maintained by Simon-Pierre Boucher · contact contact@spboucher.ai · hosted on MacLustr (www.maclustr.io). Source data remains under the license of each provider — see /sources.

Stromal Neoplasm — Research · CancerIndex

Cancers
Neoplasm
Neoplasm by Morphology
Mesenchymal Cell Neoplasm
Stromal Neoplasm

Cancer Family

Stromal Neoplasm

CI-CAN-00000360Explore in graph →

Non-malignant52 active trials2 approved drugs89 evidence items

NCIt: C6781

Overview
Statistics
Survival
Genomics3
Variants & evidence89
Drugs8
Trials355
Research
Rankings
Sources & provenance

Research activity

PubMed record counts

Each count is the number of PubMed records returned by the exact query shown, at the time it was run. Counts are research-activity signals, not quality measures.

Data not yet available

No PubMed query has been run for this entity. Counts require a MeSH-anchored query built from the entity's terminology mappings; the query string is stored with each count so it can be reproduced.

What CancerIndex knows

Trials tab
Methodology: publication counts

Literature

Linked publications (24)

Publications linked to this entity or its descendants, newest first, 25 per page. Link method and validation status are shown; 'candidate' links have not been reviewed.

pubmedProvenance

Source: PubMed (NLM)
Dataset: PubMed E-utilities
Retrieved: Sep 8, 2026
Layer: normalized (units and labels harmonized; values unchanged)

PublishedShowing 1–24 of 24 publications · bibliographic data as recorded by PubMed; abstracts are not reproduced.

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
· J Clin Oncol · 2003 · PMID 14645423 · validated civic_curation pubmed
KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
· Eur J Cancer · 2006 · PMID 16624552 · validated civic_curation pubmed
Larotrectinib in adult patients with solid tumours: a multi-centre, open-label, phase I dose-escalation study.
· Ann Oncol · 2019 · PMID 30624546 · validated civic_curation pubmed
PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
· J Clin Oncol · 2005 · PMID 15928335 · validated civic_curation pubmed
Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
· J Clin Oncol · 2006 · PMID 16954519 · validated civic_curation pubmed
Efficacy of Imatinib in Patients with Platelet-Derived Growth Factor Receptor Alpha-Mutated Gastrointestinal Stromal Tumors.
· Cancer Res Treat · 2016 · PMID 26130666 · validated civic_curation pubmed
Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
· J Clin Oncol · 2008 · PMID 18955451

Showing 1–24 of 24 publications

· validated civic_curation

A great majority of GISTs with PDGFRA mutations represent gastric tumors of low or no malignant potential.

· Lab Invest · 2004 · PMID 15146165 · validated civic_curation pubmed

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.

· Clin Cancer Res · 2006 · PMID 16551858 · validated civic_curation pubmed

Efficacy of the kinase inhibitor SU11248 against gastrointestinal stromal tumor mutants refractory to imatinib mesylate.

· Clin Cancer Res · 2006 · PMID 16638875 · validated civic_curation pubmed

KIT mutations are common in incidental gastrointestinal stromal tumors one centimeter or less in size.

· Am J Pathol · 2002 · PMID 12000708 · validated civic_curation pubmed

Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors.

· Cancer Res · 1999 · PMID 10485475 · validated civic_curation pubmed

The outcome and predictive factors of sunitinib therapy in advanced gastrointestinal stromal tumors (GIST) after imatinib failure - one institution study.

· BMC Cancer · 2012 · PMID 22439647 · validated civic_curation pubmed

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.

· J Clin Oncol · 2008 · PMID 18955458 · validated civic_curation pubmed

Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.

· Ann Oncol · 2016 · PMID 27371698 · validated civic_curation pubmed

Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial.

· J Clin Oncol · 2012 · PMID 22614970 · validated civic_curation pubmed

Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.

· Lancet · 2013 · PMID 23177515 · validated civic_curation pubmed

Ten Years of Treatment with 400 mg Imatinib per Day in a Case of Advanced Gastrointestinal Stromal Tumor.

· Case Rep Oncol · 2011 · PMID 22114577 · validated civic_curation pubmed

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.

· Clin Cancer Res · 2014 · PMID 25239608 · validated civic_curation pubmed

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.

· Clin Cancer Res · 2012 · PMID 22745105 · validated civic_curation pubmed

Gain-of-function mutations of platelet-derived growth factor receptor alpha gene in gastrointestinal stromal tumors.

· Gastroenterology · 2003 · PMID 12949711 · validated civic_curation pubmed

A potent combination of the novel PI3K Inhibitor, GDC-0941, with imatinib in gastrointestinal stromal tumor xenografts: long-lasting responses after treatment withdrawal.

· Clin Cancer Res · 2013 · PMID 23231951 · validated civic_curation pubmed

Diana et al. NPJ Precis Oncol 2023

· 2023 · PMID 36593350 · validated cbioportal_study pubmed

Dermawan et al. Clin Cancer Res 2023

· 2023 · PMID 37477937 · validated cbioportal_study pubmed